Cross-national comparison of screening mammography accuracy measures in U.S., Norway, and Spain.

Domingo, Laia; Hofvind, Solveig; Hubbard, Rebecca A.; Román, Marta; Benkese, David; Sala, Maria; Castells, Xavier

doi:http://dx.doi.org/10.1007/s00330-015-4074-8

Cross-national comparison of screening mammography accuracy measures in U.S., Norway, and Spain.

License

Citation

Domingo L, Hofvind S, Hubbard RA, Román M, Benkeser D, Sala M. et al. Cross-national comparison of screening mammography accuracy measures in U.S., Norway, and Spain. Eur Radiol. 2016 Aug;26(8):2520-8. doi: 10.1007/s00330-015-4074-8

Abstract

OBJECTIVE: To compare accuracy measures for mammographic screening in Norway, Spain, and the US. METHODS: Information from women aged 50-69 years who underwent mammographic screening 1996-2009 in the US (898,418 women), Norway (527,464), and Spain (517,317) was included. Screen-detected cancer, interval cancer, and the false-positive rates, sensitivity, specificity, positive predictive value (PPV) for recalls (PPV-1), PPV for biopsies (PPV-2), 1/PPV-1 and 1/PPV-2 were computed for each country. Analyses were stratified by age, screening history, time since last screening, calendar year, and mammography modality. RESULTS: The rate of screen-detected cancers was 4.5, 5.5, and 4.0 per 1000 screening exams in the US, Norway, and Spain respectively. The highest sensitivity and lowest specificity were reported in the US (83.1 % and 91.3 %, respectively), followed by Spain (79.0 % and 96.2 %) and Norway (75.5 % and 97.1 %). In Norway, Spain and the US, PPV-1 was 16.4 %, 9.8 %, and 4.9 %, and PPV-2 was 39.4 %, 38.9 %, and 25.9 %, respectively. The number of women needed to recall to detect one cancer was 20.3, 6.1, and 10.2 in the US, Norway, and Spain, respectively. CONCLUSIONS: Differences were found across countries, suggesting that opportunistic screening may translate into higher sensitivity at the cost of lower specificity and PPV. KEY POINTS: • Positive predictive value is higher in population-based screening programmes in Spain and Norway. • Opportunistic mammography screening in the US has lower positive predictive value. • Screening settings in the US translate into higher sensitivity and lower specificity. • The clinical burden may be higher for women screened opportunistically.